James J. Starling

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

Anne H. Dantzig, Robert L. Shepard, Jin Cao et al. · PubMed · 1996 · 328 citations

Medicine, Oncology, Pharmacology +17

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 309 citations · Full text

Medicine, Cancer Biology, Oncology +16

Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma

Vipin Yadav, Xiaoyi Zhang, Jiangang Liu et al. · Journal of Biological Chemistry · 2012 · 204 citations · Full text

Medicine, Oncology, Pharmacology +15

Selectivity of the Multidrug Resistance Modulator, LY335979, for P-Glycoprotein and Effect on Cytochrome P-450 Activities

Anne H. Dantzig, Robert L. Shepard, K L Law et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 179 citations · Full text

Medicine, Oncology, Pharmacology +17

Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

Shih-Hsun Chen, Youyan Zhang, Robert D. Van Horn et al. · Cancer Discovery · 2016 · 172 citations

Life Sciences, Molecular Biology, Oncology +15